Nandita Shangari is joining RA Capital from Novartis Venture Fund (NVF), a life science investment firm, where she was a Managing Director. Prior to her Managing Director role at NVF, Nandita held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah® Global Program Team, helping to bring this novel cell therapy to market. Nandita has also held strategic and group head roles in the Novartis Preclinical Investigative Toxicology organization. She received a B.Sc. in Biochemistry and a Ph.D. in Pharmaceutical Sciences from the University of Toronto, Canada.